Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
Clinical trial NCT02326220 · COMPLETED
Trial details
- NCT number
- NCT02326220
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-31
- Primary completion
- 2016-01-31
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.